A federal commission recommended a retooling of the US research enterprise—streamlining grant processes and embedding AI and data integration across federal science funding—to preserve national biotech leadership. The report urges modernizing grant review and leveraging AI to accelerate discovery and commercialization. Concurrently, the White House executive order launching the 'Genesis Mission' tasks DOE and other agencies with using AI to drive breakthroughs in areas including lifesaving medicines, fusion and materials science. The plan sets rapid timelines for challenge selection, resource mapping and initial progress demonstrations. Taken together, the policy moves signal heightened federal emphasis on AI‑accelerated R&D and potential shifts in funding priorities and infrastructure that could reshape academic–industry collaboration and biotech innovation pipelines.